Skip to navigation Skip to content

Clinical Trial: SAR442168

Share

Details
Type of MS: PPMS
Treatment mode of action: To improve immune function
Number of Subjects: 1320
Medication: SAR442168 (Inhibiting B-cell receptor signaling by blocking BTK disease activity)
Location: Washington
Institutions: Inland Northwest Research
610 S Sherman St. Suite 208
Spokane, WA 99202 Contact Information
Deann Dickinson, ext. 704
509-960-2818
ddickinson@inwresearch.com

Funding:

Sanofi

Description

This is a Phase 3, randomized, double-blind, 2-arm, placebo-controlled, parallel-group,
multicenter, trial to determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.